RxDoctor Payments DataLook up a doctor →

Kristin Giannini, MD

Family Medicine · Vernon, CTNPI 1881662443

Payments from drug & device makers

$28,484in general payments, 2019–2025

Across 1,710 payments — averaging $16.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$5K
  • Novo Nordisk$3K
  • AstraZeneca$3K
  • Pfizer$2K
  • GSK$1K
  • Lilly USA, LLC$1K
  • plus $13K from 54 others

What the payments were for

  • Food & beverage$28,28699%
  • Education$1981%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)350$5,022
Novo Nordisk187$3,066
AstraZeneca133$2,548
Pfizer144$1,864
GSK96$1,370
Lilly USA, LLC78$1,238
Amgen(2 entities)70$1,081
Boehringer Ingelheim35$821
Johnson & Johnson47$797
Sanofi-aventis U.S. LLC36$654
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC44$639
Otsuka America Pharmaceutical, Inc.31$591
Merck29$553
Novartis26$521
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)25$468
Astellas Pharma US Inc24$451
Lundbeck LLC26$434
Vanda Pharmaceuticals Inc.20$393
Dexcom, Inc.18$358
Takeda Pharmaceuticals U.S.A., Inc.17$331
E.r. Squibb & Sons, L.L.C.15$315
Phathom Pharmaceuticals, Inc.24$309
Abbott17$307
Amarin Pharma, Inc.18$290
Exact Sciences12$262
Biohaven Pharmaceuticals, Inc.10$255
Eisai Inc.14$244
Avanir Pharmaceuticals, Inc.9$216
Corcept Therapeutics6$214
Kowa Pharmaceuticals America, Inc.13$198
Scilex Pharmaceuticals Inc.8$161
Teva Pharmaceuticals USA, Inc.6$156
Biohaven Pharmaceutical Holding Company Ltd.8$144
Almatica Pharma LLC6$129
Idorsia Pharmaceuticals US Inc7$128
Collegium Pharmaceutical, Inc.6$115
Shield Therapeutics Inc6$114
Bayer6$108
Amneal Pharmaceuticals LLC5$89
Ardelyx, Inc.4$84
Currax Pharmaceuticals LLC5$72
Resmed Corp1$66
Neurocrine Biosciences, Inc.3$60
Radius Health, Inc.3$58
Boston Scientific2$56
Xeris Pharmaceuticals, Inc.3$56
MDD US Operations, LLC2$50
Actelion Pharmaceuticals US, Inc.2$50
Insightec,inc2$50
Adlon Therapeutics L.p.3$49
Dermira, Inc.3$49
Evoke Pharma, Inc.3$45
QOL Medical, LLC2$44
Sumitomo Pharma America, Inc.3$44
Soleno Therapeutics, Inc.2$44
Corium, LLC2$44
Antares Pharma, Inc.2$42
Cequr Corporation1$42
Axsome Therapeutics, Inc.2$40
Valinor Pharma, LLC2$39

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$28,484 in reported general payments places this provider in the 95th percentile of 588 family medicine providers in Connecticut.

See all family medicine providers in Connecticut

Medicare billing

Part B allowed, 2024
$111,251
Medicare patients
439
Services billed
1,852

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide168$213,258
Humira(Cf) PenAdalimumab21$190,945
EliquisApixaban312$173,848
Tresiba Flextouch U-200Insulin Degludec71$95,296
XareltoRivaroxaban133$94,886
MounjaroTirzepatide85$94,419
JanuviaSitagliptin Phosphate148$86,071
JardianceEmpagliflozin75$77,632
OtezlaApremilast13$72,350
RybelsusSemaglutide39$68,730
FarxigaDapagliflozin Propanediol80$57,527
TrulicityDulaglutide34$56,111
RexultiBrexpiprazole26$53,086
Trelegy ElliptaFluticasone/Umeclidin/Vilanter68$45,553
ProliaDenosumab25$44,661

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$3,066$281,988207 claims
PfizerEliquis$1,864$173,848312 claims
Lilly USA, LLCMounjaro, Trulicity$1,238$150,529119 claims
AmgenOtezla, Prolia$1,081$117,01138 claims
MerckJanuvia, Janumet Xr$553$102,898160 claims
Boehringer IngelheimJardiance, Tradjenta$821$97,270141 claims
Johnson & JohnsonXarelto$797$94,886133 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$1,370$87,284123 claims
AstraZenecaFarxiga, Brilinta, Symbicort$2,548$86,241160 claims
AbbVieLinzess, Namzaric, Restasis$5,022$53,52183 claims
Otsuka America Pharmaceutical, Inc.Rexulti$591$53,08626 claims
Astellas Pharma US IncMyrbetriq$451$30,13758 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 588 family medicine providers in Connecticut.

Other family medicine in Vernon

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →